99 results about "Intra arterial" patented technology

A constraining sheath for use around an endoprosthesis (e.g., a stent device, with or without a graft covering), which may be a balloon expandable endoprosthesis but more preferably is a self-expanding prosthesis. The endoprosthesis is coaxially enclosed within and substantially covered by the constraining sheath, which is an outer, removable tubular sheath, preferably made of ePTFE. The sheath is preferably corrugated circumferentially along at least a portion of the length of the endoprosthesis. The constraining sheath and endoprosthesis are preferably mounted together as an assembly at the distal end of a delivery means such as a catheter shaft, for delivery of the endoprosthesis to a desired location within a body conduit such as an artery. The constraining sheath is removed by the application of tension to a tensile member such as a tether to cause sequential pulling out of the corrugations followed by release and deployment of the endoprosthesis. The use of a corrugated constraining sheath in comparison to a non-corrugated sheath results in a more smoothly applied tensile force to effect the endoprosthesis release as well as requiring less maximum force.

A method and apparatus are disclosed of utilizing a source of arterial and/or arteriolar pulse waveform data from a patient for the purpose of measuring pulsus paradoxus. The arterial pulse waveform data source described is a pulse oximeter plethysmograph but can be any similar waveform data source, including intra-arterial transducer, blood pressure transducer, or plethysmograph. Through incorporation of the measurements of values, such as the area under the pulse waveform curve, that are time-domain functions of a change in height of the pulse waveform over at least a partial duration of the waveform, embodiments of the present invention represent a significant improvement upon previously described methods of measuring pulsus paradoxus and, further, produce improved accuracy in measurement of the multiple contributing variables generating pulsus paradoxus, in particular the contribution of diastolic events, to the extent that the physical signs so measured can be regarded as “Revised Pulsus Paradoxus.”

A method and device for accurately determining oxygen saturation of hemoglobin by the measurement of the optical density of a sample, such as a blood vessel, in response to illumination by light having at least three wavelengths (λi, λ2, λ3, . . . ) within a range of about 460 nm to about 523 nm. The hematocrit of a sample may be determined from optical density measurements at the three or more wavelengths in conjunction with a known path length. The device may be an intravenous or intra-arterial fiber optic catheter used to deliver the interrogating light signal to the blood and to detect the reflected signal. A method and device of determining the thickness of the retinal well using spectroscopic information are also disclosed.

An electronic anti-coagulation stent structure is disclosed. The stent structure comprises a pair of coaxial metal stents having a layer of dielectric material between the stents. A battery is operatively connected preferably near or adjacent to the upstream end upon deployment of the stent. The positive battery terminal establishes an electrical connection to the outer metal stent and the negative terminal establishes an electrical connection to the inner metal stent and this exhibits a capacitor-like properties. The inner metal stent, being negatively charged, promotes a platelet repellent, anti-thrombotic effect.

A method to serially determine changes in perfusion to tissues is provided. This method involves injecting contrast material into a catheter that is positioned in the blood supply proximal to the targeted tissue of interest, acquiring a time series of images that depicts the uptake of this contrast material within the tissue, deriving semi-quantitative or quantitative perfusion metrics based upon the time series of perfusion images, altering perfusion to the targeted tissue by means of injecting pharmacologic agents or embolic agents into the blood vessels supplying the targeted tissue, repeating the acquisition of perfusion images to serially monitor changes in tissue perfusion after each alteration, and calculating changes in perfusion metrics after each series of perfusion images. This method is used to monitor changes in perfusion to various tissues, including a diverse array of tumors. The perfusion imaging method can be acquired using magnetic resonance, x-ray computed tomography, or radionuclide imaging. The perfusion metric is serially measured during an embolization procedure as a means of measuring changes in tissue perfusion or to target an endpoint based upon a specific alteration in the calculated perfusion metric.

The utility of pulse volume measurement is expanded to detection of many conditions which have previously not been detected or have been detected using more complicated techniques. Such conditions include blood loss, septic shock, cardiogenic shock, neonatal sepsis, patent ductus arteriosus, limb ischemia, intra-aortic balloon pump performance, peripheral vascular disease, congestive heart failure, the effectiveness of vasoactive medications, syncope, dehydration, pre-eclampsia, deep vein thrombosis, thermal injuries, vascular instability due to renal dialysis, compromising of circulation to the hand caused by radial artery harvesting, changes in cardiac output, and hypertension. According to the present invention, such diagnoses can be performed by taking one measurement, by taking measurements over time to detect a change or by taking measurements before and after application of a treatment or stimulus.

An intra pelvic cancer therapeutic agent perfusion apparatus and method for administering a cancer therapeutic agent to and recovering same from a cancer tissue site within the pelvis. The tip of a first sheath is percutaneously inserted into the femoral artery and the tip of a second sheath is inserted into the femoral vein. A first balloon catheter is inserted into the aorta through the femoral artery and a second balloon catheter is inserted into the vena cava through the femoral vein. The first balloon catheter is used to block the blood flow and the second balloon is inflated to form an intravenous closed region between the site of insertion in the vena cava and a lower limb side venous site. A body fluid containing a cancer therapeutic agent is administered to the intra arterial closed region through the first sheath and is removed therefrom through the second sheath.

The present invention relates to a method for measuring arterial pressure by using pulse wave and its device. Its method is as follows: a. measuring arterial pressure value when the human palm is placed on the horizontal surface of the heart and pulse wave conduction time; b. using static fluid mechanics equation and distance of that the palm is departed from the horizontal surface of the heart to calculate the pulse wave conduction time when the human palm is placed on non-horizontal surface of the heart; c. using the above-metnioned calculated valve values to calculate the regression coefficient and constant of linear relation between arterial pressure and pulse wave conduction time; d. using the above-mentioned linear relation to measure pulse wave conduction time so as to obtain the blood pressure value of human body.

The invention discloses a shock wave generating system for an angioplasty catheter. The system includes an elongate member, wire electrodes, a non-conductive gap, each wire electrode attached to an electrical output terminal of a high voltage power source by an electrical wire extending from a terminal on an outer surface of the elongate member to the wire electrode. The system is an electrode assembly of a shock wave generating angioplasty catheter for treating calcified arteries. Shock waves are impact in nature and can impact and decompose hard calcified platelets deposited on the inner wall of the artery. Once these deposits are fragmented, the space of the arterial lumen expands, thereby improving blood flow.

A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.

Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected. At least one dose consisting of an effective amount of stem cells is administrated through intravenous (IV), intra thecal, intra-arterial, via catheter into the organ, via Myostar catheter into the heart, intracoronary, intrapericardial, and/or by direct injection into the organ. Effectiveness of the administration is monitored at selected time periods to determine whether there exists an improved clinical indication. A second dose is administered by a method that is at least invasive as that utilized in the prior dose, and the steps are repeated until the clinical indication shows improvement or until there is contraindication to continued treatment. Diseases include at least one of Ischemia, arteriosclerosis, complications of ischemia, decreased perfusion, aging or diabetes.

This invention discloses a kind of quality control method and application of Ganoderma lucidium spore oil fat emulsion. Which includes Ganoderma lucidium spore oil 2˜25%, emulsifier 0.5˜10%, isosmotic agent 0.2˜5%, the remaining content is water and the final pH of Fat emulsion is adjusted to 6˜9. The quality control method of this invention can accurately determine the content of 1,2-oleic-3-palmitic triglyceride and glycerol trioleate in the preparation, and accurately determine the ergosterol content, which serves as the method and basis for quality control of this product. Fingerprints are utilized to grasp the product quality from the overall characteristics of Chromatogram. This invention has clearly defined active ingredients, with excellent bioactivity, and is capable of tumor treatment, while improving the organism's immunity, as well as the life quality of tumor patients undergoing radiotherapy and chemotherapy, and relieving the drug toxicity after treatment. This invention is particularly suitable for both intra-arterial injection and intravenous injection, enabling the Ganoderma lucidium spore oil to directly gain access to the human blood circulation, with short time to onset and complete absorption as well as high security, reliable quality, and low drug toxicity.

The invention discloses an intravessel heating infusion device, comprising a transfusion bottle, a transmission pipe and a puncture needle; wherein, an electric heater is arranged in or on the puncture needle, and the electric heater is connected with a power supply and used for heating liquid which flows in the puncture needle. The intravessel heating infusion device does not need complicated medical equipment during the implementation process, only an ordinary drop device and a corresponding temperature monitoring device are needed for the infusion, the process is simple and convenient, a patient can be directly treated at an out-patient department without the need of being in a hospital; when in whole body hyperthermia, the speed of the temperature increase of the machine body is rapid. Blood circulation can transmit the heat to the whole body within dozens of minutes.

Embodiments of the present invention provide an improved transformation method whereby the peripheral pulse waveform is filtered to separate different phases which make up the waveform. The separate phases are transformed before being re-combined to provide an estimated intra-arterial transfer function. For example, in one embodiment the peripheral pulse waveform is filtered by a first high pass filter, and a copy of the peripheral pulse waveform filtered by a second high pass filter, having a different cut-off frequency. The two filtered waveforms may then be further processed, for example by being added back to original wave-form, and are then multiplexed together in a time division manner to provide a final waveform. For example, the part of the first filtered waveform corresponding to the systolic phase may be combined with the part of the second filtered waveform corresponding to the diastolic phase to produce the final waveform, and the respective filter cut-off frequencies may be chosen to extract characteristics of the respective phases of the heart.

The invention discloses an aorta blocking-free anastomosis auxiliary device and a using method thereof. The aorta blocking-free anastomosis auxiliary device comprises an air conveying pipe and a working air bag arranged at one end of the air conveying pipe and communicated with the air conveying pipe, and the working air bag is inserted into an aorta from the aorta punching position; when the working air bag is in a full state, the upper side face of the working air bag is tightly attached to the aorta intima, the joint of the upper side face of the working air bag and the aorta intima is located on the periphery of the circumference of the aorta hole, and a suture position is reserved on the circumference of the aorta hole. The device is simple in structure, the aorta anastomosis device is simple in structure and convenient to use, a conventional surgical suture mode is broken through, namely anastomosis (suture) of the aorta can be completed under non-blocking of the aorta, normal flowing of blood in the aorta during surgery is guaranteed, damage caused by insufficient blood supply of organs of a patient under complete blocking of the aorta is avoided, blood loss in the surgicalsuture process is reduced, and the device is more suitable for aorta calcification patients.

The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent).

The invention discloses intra-arterial medical equipment, namely a carotid artery stent system, which belongs to the field of medical apparatus and instruments. The carotid artery stent system comprises a carotid artery stent and a conveyor, wherein the carotid artery stent is implanted into a pathological blood vessel spot through the conveyor; the carotid artery stent is precompressed into an outer sheath of the conveyor, and is released to a pathological region through withdrawing the conveyor. The carotid artery stent system is characterized in that the carotid artery stent is a self-expansion laser-carved nickel-titanium superelastic alloy stent, and a stent release condition is of a mesh cylinder structure composed of multiple V unit structures, and opposite V units form a diamond mesh, and the stent of the mesh cylinder structure consists of three sections, wherein every three diamond meshes of big mesh sections at the two ends have a cross structure, and every two diamond meshes of small mesh sections in the middle have a cross structure, and the stent shrinks in a peak-to-valley manner when being bent; the top end of the conveyor is of a biconical head end shape. Compared with the prior art, the stent has the advantages of more excellent blood vessel adherence performance and flexibility, good non-deformability and good durability and the like by utilizing the design characteristics of the stent itself.

The invention is concerned with a kind of vascular endothelial cell aneurysm bracket and its produce method, belonging to biology medical treatment material field. This method takes It adheres the amplified vascular endothelial cell of blood vessel gathered from endoderm of body vena on the surface of metal aneurysm bracket with innocuous macromolecule biomaterial coating with innocuous macromoleculem, biocompatibility and biodegradable characters. It speeds the producetion and cover of rebirth endodermis to the neck of tumour after setting up the bracket, reduces the recrudescence of aneurism and avoids the straitness of artery with tumour, enhances the cure rate to aneurism, especially to intracranial aneurysm, and reduces the thrombosis inside of artery. It overcomes the shortages of stainless steel bracket without the problem of immunogenicity and ethic. This mature technology with low cost is benefit to enhance and drive the development of new-style stuff to endovascular treatment and the interventional therapy of intracranial aneurysm.